Filza Nur Athirah Tar'ali, Aina Amanina Abdul Jalil, Nor Safwan Hadi Nor Afendi
BPharm, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia.
BPharm, MClin Pharm, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia. Email:
Malays Fam Physician. 2024 Jan 6;19:2. doi: 10.51866/oa.415. eCollection 2024.
During the coronavirus disease (COVID-19) pandemic, there was a widespread public misconception regarding ivermectin use in managing the disease. There is no approval of ivermectin as COVID-19 treatment by the Food and Drug Administration, and the adverse effects of the drug are alarming. This study aimed to evaluate the knowledge and attitude towards and prevalence of ivermectin use as COVID-19 treatment among the Malaysian population.
This cross-sectional study was conducted among 391 Malaysians aged ≥18 years. A validated online self-administered questionnaire disseminated via Google Forms was used to evaluate the knowledge and attitude towards and prevalence of ivermectin use as COVID-19 treatment. The socio-demographic characteristics and knowledge and attitude towards and prevalence of ivermectin use among the respondents were evaluated through descriptive analysis. The chi-square test was used to identify the association between the variables.
The respondents had moderate levels of knowledge and attitude towards ivermectin use, while the prevalence of ivermectin use was 3.58%. The respondents' sex (P=0.014), age (P=0.012) and monthly income (P=0.049) were significantly associated with their level of knowledge. The respondents' sex (P=0.04) was significantly associated with their level of attitude. Conversely, no socio-demographic characteristics were significantly associated with the prevalence of ivermectin use as COVID-19 treatment.
The majority of Malaysians have moderate levels of knowledge and attitude towards ivermectin use as COVID-19 treatment, with a low prevalence of actual use.
在冠状病毒病(COVID-19)大流行期间,公众对使用伊维菌素治疗该疾病存在广泛的误解。美国食品药品监督管理局未批准将伊维菌素用于治疗COVID-19,且该药物的不良反应令人担忧。本研究旨在评估马来西亚人群对使用伊维菌素治疗COVID-19的知识、态度及使用情况。
本横断面研究在391名年龄≥18岁的马来西亚人中进行。通过谷歌表单分发的一份经过验证的在线自填问卷,用于评估对使用伊维菌素治疗COVID-19的知识、态度及使用情况。通过描述性分析评估受访者的社会人口学特征以及对伊维菌素使用的知识、态度和使用情况。采用卡方检验来确定变量之间的关联。
受访者对伊维菌素使用的知识和态度水平中等,而伊维菌素的使用率为3.58%。受访者的性别(P=0.014)、年龄(P=0.012)和月收入(P=0.049)与他们的知识水平显著相关。受访者的性别(P=0.04)与他们的态度水平显著相关。相反,没有社会人口学特征与将伊维菌素用作COVID-19治疗的使用率显著相关。
大多数马来西亚人对使用伊维菌素治疗COVID-19的知识和态度水平中等,实际使用率较低。